Welcome to our dedicated page for Rafael Holdings SEC filings (Ticker: RFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to track both a biotech pipeline and commercial real-estate income in one report? Rafael Holdings’ SEC disclosures weave R&D milestones, infusion-technology sales and lease agreements into hundreds of pages. Finding where drug-trial costs sit, or when a building lease renews, can drain hours.
Stock Titan’s platform delivers the solution. Our AI parses every Rafael Holdings annual report 10-K simplified, flags segment footnotes in each Rafael Holdings quarterly earnings report 10-Q filing, and sends instant alerts on Rafael Holdings 8-K material events explained. Interactive summaries translate accounting language into plain English, so understanding Rafael Holdings SEC documents with AI feels effortless. Need to monitor management moves? Real-time dashboards stream Rafael Holdings Form 4 insider transactions real-time, letting you spot trends before the market reacts.
Here’s what investors uncover:
- Clinical spend vs. progress for lead oncology assets in the 10-K
- Lease revenue swings broken down by property in the 10-Q
- Board proposals and Rafael Holdings proxy statement executive compensation details
- Every Rafael Holdings insider trading Form 4 transactions alongside AI commentary
Whether you’re comparing quarter-over-quarter R&D burn, studying Rafael Holdings earnings report filing analysis, or vetting Rafael Holdings executive stock transactions Form 4 before a catalyst, our comprehensive, real-time feed keeps you ahead—all in one place and explained simply.
Rafael Holdings (RFL) is asking stockholders to vote at its Annual Meeting on January 8, 2026 to elect six directors, ratify CohnReznick LLP as auditor for the fiscal year ending July 31, 2026, and approve an amendment to the 2021 Equity Incentive Plan adding 1,000,000 shares of Class B Common Stock for future awards. Stockholders of record on November 11, 2025 may vote in person or by proxy.
As of the record date, Rafael had 51,762,801 shares outstanding, consisting of 787,163 Class A shares with three votes each and 50,975,638 Class B shares with one‑tenth vote each, voting together on all proposals. Howard S. Jonas beneficially owns all Class A shares and 14,010,522 Class B shares, representing 28.6% of Class B and 50.4% of aggregate voting power, so the company qualifies as a NYSE “controlled company.”
The Board states it does not rely on controlled‑company exemptions, and a majority of directors and all Audit, Compensation, Corporate Governance and Nominating Committee members are independent, with Markus Sieger serving as lead independent director. The proxy also details director and executive pay, including 2025 compensation of $294,000 for Howard Jonas, $592,912 for former CEO William Conkling and $527,353 for CFO David Polinsky, along with related‑party transactions and a 2025 net loss of $30.6 million.
Rafael Holdings (RFL)director effective 10/23/2025. The filing states the reporting person beneficially owns 0 shares of Class B Common Stock on a direct (D) basis and lists no derivative securities. The form is identified as filed by one reporting person.
Rafael Holdings (RFL) filed its annual report, highlighting a pivot to biotech led by Trappsol® Cyclo™ for NPC1. The company completed the Cyclo merger on March 25, 2025 and is running a global, double-blind Phase 3 trial that fully enrolled 94 patients; a June 2025 DMC review found the therapy well tolerated and recommended continuing to 96 weeks. An open-label sub‑study in patients under 3 years showed mostly stabilization or improvement on CGI‑S at 48 weeks, with manageable adverse events.
Beyond Trappsol® Cyclo™, Rafael owns majority stakes in LipoMedix, Cornerstone, Rafael Medical Devices, and Day Three. Rafael Medical Devices received FDA 510(k) clearance on December 11, 2024 for its VECTR System for minimally invasive ligament/fascia release. Cornerstone was restructured in March 2024, making Rafael a 67% owner. Day Three Labs sold certain assets and licensed Unlokt™ applications for a
As context, non‑affiliate market value was about
Rafael Holdings (RFL)Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed. The materials also contain forward‑looking statements accompanied by cautionary language.
Rafael Holdings appointed Alan Grayson to its Board on October 23, 2025, and to the Compensation, Corporate Governance and Nominating committees. Director Markus Sieger was named to the audit committee and elected its Chairman. These appointments fill vacancies following the recent passing of Stephen Greenberg. A press release dated October 28, 2025, was filed as Exhibit 99.1.
Rafael Holdings (RFL) disclosed a Form 4 for its Chief Financial Officer. On 10/25/2025, 4,180 shares of Class B common stock were withheld for taxes upon the vesting of restricted stock, coded F, at a price of $1.35 per share.
Following this transaction, the CFO beneficially owns 260,641 shares directly. This total consists of 76,882 shares held directly, 82,509 fully vested restricted shares, and 101,250 unvested restricted shares.
The unvested restricted shares vest as follows: 6,250 quarterly from December 21, 2025 through December 21, 2026; 10,000 on each of October 25, 2026 and October 25, 2027; and 12,500 on each of January 13, 2026, January 13, 2027, January 13, 2028, and January 13, 2029.
Rafael Holdings, Inc. (RFL) Chief Financial Officer David Polinsky reported a non-open-market disposition of 1,284 Class B common shares on 09/23/2025 described as shares withheld by the issuer to satisfy tax obligations upon the vesting of restricted stock at an effective price of $1.48 per share. After this withholding, Mr. Polinsky beneficially owns 264,821 shares, consisting of 76,882 shares held directly, 76,689 fully vested restricted shares, and 111,250 unvested restricted shares with specified vesting dates through January 13, 2029. The Form 4 was signed by power of attorney on 09/25/2025.
Rafael Holdings, Inc. (RFL) Chief Financial Officer David Polinsky reported a transaction on 09/21/2025 in Class B common stock. The filing shows 1,970 shares were disposed at $1.49 per share, representing shares withheld by the issuer for tax purposes upon the vesting of restricted stock. After the reported transaction, Polinsky beneficially owns 266,105 shares, which include 76,882 shares held directly, 74,223 fully vested restricted shares, and 115,000 unvested restricted shares subject to a defined vesting schedule through January 13, 2029.
The disposition was reported on 09/22/2025 and appears to be a routine tax-withholding action tied to vesting rather than an open-market sale.
Rafael Holdings, Inc. director and 10% owner Jonas Howard S reported a non-derivative transaction on 09/13/2025. The filing shows 9,905 shares of Class B common stock were disposed at a price of $1.345 using transaction code F. After the reported transaction, the filing lists 267,707 shares beneficially owned by the reporting person directly.
The Form 4 also discloses a range of indirect holdings: multiple trusts and partnerships hold substantial Class B and Class A shares, including a total of 12,299,207 Class B shares reported for one trust and 787,163 Class A shares held indirectly by a partnership where the reporting person has sole voting and dispositive power. The filer signed via power of attorney on 09/16/2025.
FAQ
What is the current stock price of Rafael Holdings (RFL)?
What is the market cap of Rafael Holdings (RFL)?
